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ABSTRACT 
 
Equine infectious anemia virus (EIAV) is a member of the lentivirus group of the family 
Retroviridae.  EIAV encodes a highly glycosylated SU (surface) protein with 
interspersed conserved and variable regions.  The variable regions are thought to play a 
key role in virulence determination and virus neutralization.  The role of SU in virulence 
is thought to be based on induction of cytokine gene expression upon binding of the 
virus to permissive cells leading to clinical signs that are associated with the infection.    
The proposed experiments will look specifically at one variable region (V6) of SU.   My 
hypothesis was that V6 plays a major role in virulence by inducing cytokine induction 
upon binding.  I used two EIAV strains with distinct phenotypes (virulent EIAV17 and 
avirulent EIAV19) to test the contribution of V6 to increased cytokine induction.   The 
findings of these studies will aid in the long term goal of vaccine development and 
potential treatments for EIAV and other retroviruses.   
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CHAPTER I 
INTRODUCTION 
 
1.1 History of Equine Infectious Anemia  
Equine Infectious Anemia Virus (EIAV) was first identified in France in 1843 and 
recorded again in 1861.  By 1870, the virus had spread throughout Europe, Russia, part 
of Africa and most of Asia.  In the first decade of the 1900’s, Japan had the first 
recorded epidemics with over 300 horses dying per year of the infection.  EIAV was 
assigned a viral etiology (classified at a filterable agent) in 1904 which made it the first 
animal virus to be so classified {Montelaro et al., 1993; Leroux et al., 2004; Issel et al., 
1993}.  
 
The first reported case of EIAV in North America was in Wisconsin in 1888.     The 
virus spread to Wyoming in the early 1890’s, leading to the first recorded epidemic in 
North America in 1901.  By the late 1900’s, the virus had spread to 10 states that 
coincided with the annual cattle drives from Texas to Minnesota and Montana.  A period 
of quiescence followed, leading many to believe that the virus was no longer a threat to 
the horse population.  The virus was reported in New England in 1935 and a researcher 
confirmed the presence of EIAV in 29 states by 1941 via horse-inoculation test.  The 
silent spread surprised many in the horse industries since there was still very limited 
knowledge of the pathogenesis of the virus.  The second major outbreak in North 
America occurred in 1947 at a race-track in New Hampshire.  Seventy-seven 
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Thoroughbred horses died or were euthanized.  The outbreak was traced to a horse 
brought from Florida.  That outbreak was probably the single most important incident to 
raise public awareness about the devastating effects of EIAV and prompted new research 
and regulations to help safeguard horses from infection {Clark et al., 2003}.   
 
By the 1960’s, EIAV was recognized as a major virus impacting equids as widespread 
epidemics were occurring at racetracks in Maryland, Florida, Washington, and Illinois.  
Most epidemics were explosive in nature and more than one horse died prior to the 
disease being detected.  In 1965, the United States Livestock Sanitary Association along 
with other national veterinary and horse industry groups developed a positive uniform 
plan for quelling the disease.  The “Prospectus on Equine Infectious Anemia with 
Guidelines” was instrumental in halting the spread by the latter part of 1966 {Clark et 
al., 2003}. 
 
In 1970, Dr. Leroy Coggins of Cornell University developed the first accurate laboratory 
test for diagnosing the disease {Nakajima et al., 1972; Montelaro et al., 1993}.  
Previously, diagnosis was confirmed using the horse inoculation test which involved 
taking the blood of a sick horse and injecting it into a healthy horse and waiting to see if 
the healthy horse developed symptoms {Montelaro et al., 1993; Issel et al., 1993}.  The 
testing was labor and time intensive and resulted in more infected horses.  The 
development of the “Coggins Test” was a huge breakthrough for diagnosis and disease 
control.  The test is an agar gel immunodiffusion test which detects antibodies to the 
 3 
 
virus {Nakajima et al., 1972; Montelaro et al., 1993; Issel et al., 1993}.  In 1973, the 
USDA designated the Coggins Test the official test for determining the presence of 
EIAV, established a procedure for certifying a network of laboratories qualified to run 
the test, and prohibited interstate travel of EIAV positive horses except for transport to a 
slaughterhouse, quarantine facility or research facility.  A quarantine directive was 
issued for positive horses requiring the infected animal to be housed in approved 
quarters until death or euthanasia.  Many in the horse industry fought the directive since 
inapparent carriers were testing positive but not showing signs of the disease.  The 
directive and disease control programs have proven effective at decreasing the incidence 
of disease nationwide.  In Florida, the incidence of new cases decreased from 12% in 
1970 to 0.016% in 2000.  This downward trend is a direct result of effective disease 
control activities, strict enforcement of EIA regulations, and strong support of the equine 
industry.  Until a vaccine becomes available in this country, control programs are the 
only viable option to reduce the risk of transmission from virus-infected equines {Clark 
et al., 2003; Montelaro et al., 1993}.     
 
For many decades after its discovery, research on EIAV was restricted due to lack of 
reliable in vitro systems for the isolation, propagation, and quantitation of the virus 
{Montelaro et al., 1993; Issel et al., 1993}.  In the late 1960’s, Japanese researchers 
discovered that EIAV could be propagated in vitro in mixed cultures of equine 
leukocytes {Montelaro et al., 1993}.  The research then focused on the kinetics of viral 
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persistence in EIAV-infected horses with the discovery of the phenomenon of antigenic 
variation of EIAV in horses manifesting the chronic stages of disease.   
 
Studies in the early 1970’s were focused on developing and evaluating the efficacy of a 
live attenuated EIAV vaccine in protecting against antigenically distinct strains of virus.  
Early observations in vaccine evaluation demonstrated that horses progressing from 
chronic EIAV to the inapparent stage of infection were resistant to the development of 
disease after trial experimental challenges with EIAV {Taylor et al, 2010}.  
Unfortunately, it was shown that attenuated EIAV vaccine was not able to provide broad 
protection against challenge with variants of EIAV {Li et al., 2003; Montelaro et al., 
1996}.   As a result, most countries shifted their focus from immunoprophylaxis of the 
equine population to identification and isolation of infected animals.   Only China and 
Cuba have large-scale vaccine programs with an attenuated strain.  The large scale 
application of the attenuated EIAV vaccine has been hailed a success in China since it 
was able to prevent and/or control EIA infections with no observable reversion or 
vertical transmission {Wang et al., 2010}.  However, the use of an attenuated vaccine 
eliminates the usefulness of the Coggins test and prevents vaccinated horses from 
entering countries that require a negative EIA antibody test for entry {Montelaro et al., 
1993}.  
 
The focus of research changed direction in the late 1970’s and early 1980’s with the 
advancement of molecular techniques that allowed the virus to be characterized.  In 
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1976, it was discovered the virus is a retrovirus and a member of the lentivirus subfamily 
{Montelaro et al., 1993}.  Also critical was the development of an experimental 
infection and disease model in Shetland ponies.   Over the past decade, one facet of 
EIAV research has focused on mapping the genome and understanding the pathogenesis 
of infection.  An interesting area of study is the discovery of virulence factors that may 
lead to new preventative and therapeutics measures to eliminate the incidence of new 
infections in the future. {Tagmyer et al., 2008; Lim et al., 2005, Craigo et al., 2007; 
Covaleda et al., 2010; Howe et al., 2005}      
   
1.2 Virus Replication and Pathogenesis 
EIAV is a macrophage-tropic lentivirus of the family Retroviridae.  Much of the 
pathogenesis of EIAV is directly related to the replication cycle of a retrovirus. EIAV 
replication starts with attachment to the cell surface and endocytosis of the infectious 
particle. Release of the viral core to the cytoplasm is rapidly followed by reverse 
transcription of the RNA genome. This process is accomplished by the virally encoded 
reverse transcriptase (RT) that is present in the viral core.  The product of reverse 
transcription is a molecule of linear double stranded DNA that remains associated with 
the core, most notably with the virally encoded integrase (IN).  After entry into the 
nucleus, successful integration of the EIAV genome into the host genome is required for 
production of new virions. The process of integration has important biological 
consequences. The viral genome is replicated along with cellular DNA, thus is passed to 
daughter cells during cell division.  In the absence of transcription the virus is latent, 
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thus infected cells are not targets of the immune response. In addition, maintenance of 
the provirus is not effected by treatments with antiretroviral drugs.  Thus EIAV causes a 
persistent, life-long infection in equids for which there is no treatment or cure.  Virus 
elimination can be achieved only by strict isolation or euthanasia of infected animals.  
 
EIAV is spread via mechanical transmission of infected blood.  EIAV is found 
throughout the world with the highest prevalence in geographical areas with warm 
climates; hence the common name for the disease is swamp fever {Montelaro et al., 
1993}.  Natural transmission is via insect vectors such as biting flies but transmission 
may also occur from contaminated needles and blood products and/or improper 
sterilization of instruments between horses.  EIAV is also transmitted transplacentally 
and via colostrum and milk. {Montelaro et al., 1993} 
 
Three distinct stages of infection (acute, chronic and inapparent) are commonly 
recognized.  The acute stage usually occurs in the first 30 days post-infection and is 
characterized by marked viremia, high fever, anorexia, and thrombocytopenia.  Clinical 
signs are nonspecific and depend on the age, health, and species of the animal.  Foals are 
more susceptible than adults and donkeys and mules rarely develop clinical signs.  Mild 
cases in horses may produce a fever that lasts less than 24 hours while severely affected 
horses can develop a high refractory fever and anorexia along with depression, 
weakness, and ataxia.  The acute stage is rarely fatal in naturally infected animals.    
Following the acute infection, most infected animals progress to the chronic stage.  The 
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chronic stage is the hallmark of EIAV and is characterized by recrudescing episodes of 
prominent viremia, anorexia, edema, pancytopenia, hemorrhages, diarrhea, 
glomerulonephritis, and lethargy.    Each episode lasts approximately 5 days and the 
time intervals between episodes increase over the first year post infection.  The 
development of clinical signs and the severity of disease are dependent on age and health 
of the animal as well as the strain and dose of the infecting virus.  After the first year, 
infected animals often become clinically quiescent, lifelong inapparent carriers.  An 
animal in the inapparent stage has gained immunological control of the virus, but 
remains infectious to naïve animals. Clinical signs may reoccur if the animal becomes 
stressed or develops a concurrent illness. {Equine, 2009; Tagmyer et al., 2008; 
Montelaro et al., 1993}. 
 
Equine macrophages are the predominant cell type for replication and viral spread in the 
infected animal.  The unique nature of macrophages and their role in the immune 
response impact EIAV pathogenesis.   The highest levels of EIAV are   found in liver, 
spleen, lymph nodes, and bone marrow in the acute and chronic stages of the disease, as 
these tissues are rich in tissue macrophage {Harrold et al., 2000}.  The kidneys and 
peripheral blood also contain virus during the acute stage but at much lower levels.  
EIAV infects peripheral blood mononuclear cells (PBMCs) but viral replication and 
release do not occur until the cells have differentiated into mature macrophages {Maury, 
1994}. Studies have shown that infection of normal and immune compromised foals 
results in an initial viremia that reaches maximum titers of 104-105 TCID50 per ml at 10-
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12 days post-infection {Perryman et al.,1988}.  In cases of chronic EIA, the quantity of 
virus during viremic episodes ranges from 103-106 TCID50 per ml {Montelaro et al., 
1993}.  When an animal is afebrile viral antigen and viral DNA are difficult to detect in 
tissue and PBMC’s; levels of virus are reduced to <1-103 TCID50 per ml {Montelaro et 
al., 1993}.  Latently infected macrophages serve as a viral reservoir for recurrent disease 
episodes.  In vitro EIAV infection has a cytopathic effect on macrophages which may 
correlate in vivo with leucopenia, anemia, and thrombocytopenia. {Lim et al., 2005; 
Payne et al., 2004; Covaleda et al., 2010; Sellon et al.,1992; Craigo et al.,2007; Chung et 
al., 2004; Tornquist et al., 1997}    
 
1.3 EIAV Particle and Genome Organization 
Genetically, EIAV is most similar to other retroviruses in the lentivirus group.  These 
include feline immunodeficiency virus (FIV), visna-maedi of sheep and goats, simian 
immunodeficiency virus (SIV), and human immunodeficiency virus (HIV). EIAV is a 
somewhat unique lentivirus in that symptoms appear quickly, within 1-4 weeks post 
infection, rather than months or years later.  Thus EIAV has served as a model for 
lentivirus persistence, pathogenesis and vaccine development {Tagmyer et al., 2008; 
Taylor et al, 2010}.  
 
The EIAV virion (Figure 1.1) is approximately 100nm in diameter and consists of a lipid 
enveloped encasing an oblong core that contains two copies of single stranded RNA 
{Montelaro et al., 1993}.  The EIAV surface projections are composed of two env-
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encoded glycoproteins, a heavily glycosylated protein of 90kDa (gp90) and a membrane 
spanning 45kDa glycoprotein (gp45) {Montelaro et al., 1993}.  EIAV gp90 is now 
commonly referred to as the surface unit (SU) glycoprotein of the virus and gp45 the 
transmembrane (TM) glycoprotein {Montelaro et al., 1993}.  EIAV SU and TM 
molecules associate via noncovalent interactions thus SU can be lost during virus 
purification{Montelaro et al., 1993} The EIAV matrix (MA) protein is located on the 
cytoplasmic side of the membrane and serves as the bridge between the cytoplasmic tail 
of TM and the capsid (CA) protein that forms the viral core {Montelaro et al., 1993}. 
 
 
Figure 1.1: EIAV virion. Abbreviations: LTR, long terminal repeat; MA- matrix protein; 
CA- capsid protein; NC- nucleocapsid protein; PR, protease; RT- reverse transcriptase; 
DU- dUTPase; IN- integrase;  SU- surface unit glycoprotein; TM- transmembrane 
glycoprotein.  
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Packaged inside the core are two copies of genomic RNA in association with the basic 
nucleocapsid (NC). Also present in the core are a few copies each of virally encoded 
protease (PR), RT and IN. 
EIAV genome is 8.2kb which is the smallest and simplest of all lentiviral genomes 
making it a useful model to study lentiviral replication and pathogenesis (Figure 1.2) 
{Montelaro et al., 1993; Leroux et al., 2004}. Lentiviral transcription is regulated by 
long terminal repeats (LTR) {Leroux et al., 2004}. LTR sequences are  a key component 
in cell tropism and virulence with clear differences between fibroblast culture adapted 
and field strains {Payne et al., 1999; Payne et al., 2004; Maury et al., 2005; Maury et al., 
1998; Maury et al., 2007; Montelaro et al. 1993}. Transcription of the viral genome 
generates an unspliced mRNA from which the Gag and Pol polyproteins are produced. 
This unspliced mRNA is also packaged into new virions. The env gene products (SU and 
TM) are produced from a singly spliced mRNA. A family of multiply spliced mRNAs 
encodes the nonstructural proteins Tat, Rev and S2. 
 
1.3.1. Viral Proteins 
1.3.1.1 Gag 
The Gag polyprotein is the precursor molecule to the MA, CA and NC proteins.  Gag 
polyproteins are synthesized in the cytoplasm and transported to the plasma membrane 
where they form immature budding particles {Puffer et al., 1998}.  The assembly of Gag 
precursor proteins (Pr55) on the plasma membrane is essential in that this process drives 
assembly and virus budding from the host cells {Leroux et al., 2004; Provitera et al., 
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2000}.  Maturation of the virion to an infectious particle occurs either during or 
immediately after budding when the Gag polyproteins are processed by the virus-
encoded protease {Puffer et al., 1998; Provitera et al, 2000}.  
 
1.3.1.2 Pol 
The EIAV Gag-Pol precursor (Pr180gag/pol) is encoded from unspliced mRNA. This 
longer polyprotein is synthesized via a ribosomal frame shift at a site upstream of the 
Gag stop codons.  Pr180gag/pol is important as it includes the enzyme reverse transcriptase 
(RT), which is essential for the synthesis of viral DNA from the RNA genome. 
Pr180gag/pol  processes both precursor polyproteins, and the virally encoded  dUTPase 
(DU) (essential for replication in non-dividing monocyte-derived macrophages)and the 
integrase (IN) responsible for integrating the dsDNA copy of the retroviral genome into 
the host chromosome {Leroux et al., 2004; Lichtenstein et al., 1995; Threadgill et al. 
1993}.       
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Figure 1.2: Organization of the EIAV proviral genome.  Abbreviations: LTR, long terminal 
repeat; MA- matrix protein; CA- capsid protein; NC- nucleocapsid protein; PR, protease; RT- 
reverse transcriptase; DU- dUTPase; IN- integrase;  SU- surface unit glycoprotein; TM- 
transmembrane glycoprotein. 
 
1.3.1.3 Env 
EIAV env gene encodes the SU and TM envelope glycoproteins.  The SU protein is 
highly glycosylated with pathogenic strains, such as EIAVWY, containing at least 17 
potential N-linked glycosylation sites in their SU coding sequences {Cook et al., 2013}.  
Approximately half of the molecular weight of EIAV SU is composed of glycosylated 
residues {Cook et al., 2013}.  Many of the potential N-linked glycosylation sites in SU 
are subject to change during the course of the infection {Leroux et al., 2001}.  SU also 
contains neutralizing epitopes, as demonstrated by mouse monoclonal antibodies, and is 
often referred to as the principal neutralizing domain or PND {Ball et al., 1992; Cook et 
al., 2013; Hussain et al., 1998}.   SU proteins mediate attachment and entry into 
permissive cells, and are major targets of the immune response.  The host receptor for 
EIAV is ELR-1, a member of the tumor necrosis factor family of receptor proteins 
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{Cook et al, 2013; Ball et al., 2005; Zhang et al, 2005}.  In vitro experiments have 
demonstrated that EIAV-receptor entry is mediated by a low-pH endocytic pathway 
{Cook et al., 2013; Brindley et al., 2008; Jin et al., 2005}.  
  
Throughout the course of infection, initial and recrudescing, SU is able to undergo 
significant changes in sequence without compromising function.  The selective force 
driving the evolution of SU is the host immune system {Cook et al., 2013}.  EIAV was 
the first lentivirus to be associated with “antigenic drift” as each distinct febrile episode 
in an infected equid is caused by genetically and antigenically distinct SUs {Cook et al., 
2013; Leroux et al., 1997, 2001; Craigo et al., 2010}.  SU variation can be striking and 
viral quasispecies or swarms emerge in the infected host {Leroux et al., 2004; Craigo et 
al., 2007; Craigo et al., 2009}.  Based on virus neutralization studies, the development of 
env quasispecies is responsible for the discrete febrile episodes typical of EIA. Each 
febrile episode is associated with antigenic variants that evade established immune 
surveillance {Craigo et al., 2010}. Comparisons of SU sequences reveal the presence of 
discrete variable and conserved regions within the protein {Payne et al., 1987}. 
 
1.3.1.4. Regulatory Proteins 
EIAV encodes 3 regulatory proteins: Tat, Rev, and S2.  Tat interacts with the LTR 
through the trans-activation response element (TAR) and is essential for efficient 
transcription {Rosin-Arbesfeld et al., 1998}.  Rev is a regulator of viral gene expression 
acting post-transcriptionally to allow the essential translocation of unspliced and 
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partially spliced mRNA from the nucleus to the cytoplasm {Leroux et al., 2004}. S2 is a 
cytoplasmic protein that may interact with the Gag protein but whose exact role has not 
been determined {Covaleda et al., 2010; Leroux et al., 2004}.   
 
1.3.1.4.1 Tat 
The transactivator of transcription (Tat) is expressed from a spliced mRNA. Tat exon 1 
derives from the 5’end of the genome while the location of exon 2 is between the pol and 
env genes. Tat enhances the elongation efficiency of the host RNA polymerase {Cook et 
al., 2013}.  EIAV Tat functions in a similar manner to HIV-1 Tat.  It interacts with the 
nascent mRNA transcript by binding to a short RNA hairpin structure called the trans-
activation responsive (TAR) element. This interaction serves as a scaffold for additional 
cellular proteins with the end result being phosphorylation of the C-terminus of RNA 
polII, enhancing its elongation efficiency by 100 to 1000-fold {Leroux et al., 2004}. 
 
1.3.1.4.2 S2  
S2 is a 65 amino acid protein synthesized from a multiply spliced mRNA. The S2 coding 
region begins in between the pol-env intergenic region and overlaps the N-terminus of 
env {Leroux et al., 2004; Covaleda et al., 2010}.  The S2 protein is found in all isolates 
of EIAV; its presence is highly conserved in the genome suggesting its importance in the 
virus replication cycle {Leroux et al., 2004}.  S2 is mainly localized in the cytoplasm 
and is thought to interact with the EIAV Gag precursor {Covaleda et al., 2010}.  S2 is 
not required for viral replication in vitro in equine cell lines including equine monocyte 
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derived macrophages (eMDM) which are the primary target for replication {Leroux et 
al., 2004; Covaleda et al., 2010}.  However, the importance of S2 in in vivo viral 
pathogenesis has been consistently demonstrated in the Shetland pony model {Leroux et 
al., 2004; Covaleda et al., 2010; Fagerness et al., 2006}.  Also, it has been demonstrated 
that pro-inflammatory cytokine expression is increased in equine macrophages that have 
been infected with EIAVWY as compared to macrophages that have been infected with a 
mutant EIAV that is lacking S2 {Covaleda et al., 2010; Cook et al., 2013}. 
 
1.3.1.4.3 Rev 
Rev, regulator of expression of viral proteins, acts post-transcriptionally by allowing 
nuclear export of partially spliced and unspliced RNA from the nucleus to the cytoplasm 
{Cook et al., 2013; Leroux et al., 2004}.  Rev, also produced from a multiply spliced 
mRNA, has 2 exons. Exon 1 is located near the 5’-end of the env gene while exon 2 
overlaps the TM coding region. Rev is essential for expression of structural proteins and 
thus virus production {Leroux et al., 2004}.  Rev binds to a highly structured region of 
the EIAV genome called the rev response element (RRE). The RRE is present in 
unspliced and singly spliced mRNAs and multiple copies of Rev bind this region, Rev 
binding suppresses splicing and facilitates passage of viral mRNA across the nuclear 
membrane {Leroux et al., 2004; Cook et al., 2013}.  Thus Rev regulates its own 
expression.  In the absence of Rev, viral mRNAs are spliced to form Tat and Rev 
mRNAs.  As the level of Rev in the cell increases, viral mRNA splicing is suppressed 
{Leroux et al., 2004}. 
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1.4 EIAV SU and its Variable Regions 
EIAV SU (Figure 1.3) has 8 variable regions, V1-V8, and changes in these regions have 
been shown to allow the virus to evade or escape neutralizing antibodies {Tagmyer et 
al., 2008; Souza et al., 2009; Craigo et al., 2007}.  In early studies, Ball et al. localized 
virus neutralizing epitopes to variable regions of SU {Ball et al., 2005}.  Tagmyer et al. 
showed that V3 and V4 contained major neutralization epitopes, with V3 the principal 
neutralization domain {Tagmyer et al., 2008}.  Studies by Souza et al. identified 2 
neutralizing epitopes in V3, one in V5 and possibly one in V6.  In vaccine trials, some 
protection against EIAV challenge can be measured when horses are challenged with 
homologous, but not heterologous, Env bearing viruses {Craigo et al., 2007; Li et al., 
2003}.  Thus successful vaccine development for lentiviruses must account for both 
preexisting and post-vaccination accumulations of Env mutations in the virus population 
{Tagmyer et al., 2008; Payne et al., 2004; Li et al., 2003}. 
 
 
 
Figure 1.3- Constant and variable regions in the gp90.  Diagram showing the localization of 
variable regions within SU (gp90) along with potential N-linked glycosylation sites and 
neutralizing determinants (including the principal neutralizing determinant PND) in a fibroblast-
cell adapted variant of EIAVwy (Cook et al., 2013) 
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1.4.1 SU Sequence Variation and Virulence 
In addition to roles in immune escape and avoidance, EIAV env variation has a 
measurable effect on virus virulence.   This was demonstrated by Fuller and Payne in a 
Shetland pony model using molecular clones of EIAV. They showed that infection with 
virus stocks derived from clones differing in only in env sequences resulted in distinct 
disease outcomes {Payne et al., 1994; Payne et al., 1998}. The EIAV17 virus stock is 
acutely virulent, usually producing severe disease within 10 days post-infection. In 
contrast the EIAV19/17LTR virus stock lacks acute virulence, replicating only to very low 
titers in ponies. These two viruses have identical LTRs, gag, pol and S2 sequences, and 
only differ in their env regions (Appendix I, Figure 1).  Further, when viruses chimeric 
in the env region were generated, a virus with its SU region derived from EIAV17 and its 
TM derived from EIAV19 (EIAV 17SU/19TM) produced acute disease; while virus with SU 
derived from EIAV19 and TM from EIAV17 (EIAV 19SU/17TM) did not {Payne et al., 
2004}.  EIAV17, EIAV19/wyoLTRs and the chimeric env viruses replicated to similar levels 
in cultured equine monocyte-derived macrophages (eMDM) suggesting that their 
intrinsic replication rates might not account for the observed differences in virulence 
properties {Covaleda et al, 2010}. These results focused attention on SU sequences. 
 
1.4.2 SU Sequence Variation and Cytokine Expression 
1.4.2.1 In vitro Studies 
In a study using the EIAV17 and EIAV19 virus stocks, Lim et al. showed that EIAV17, but 
not EIAV19, elicits the induction of pro-inflammatory cytokines when cultured equine 
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monocyte derived macrophage (eMDM) are treated with virus for short periods of 
time{Lim et al., 2005}. EIAV17 exposure significantly increased expression of 
interleukin (IL)-1α, IL-1β, IL-6, IL-10 and tumor necrosis factor (TNF)-α whereas 
avirulent EIAV19 failed to induce expression of these cytokines significantly above 
control levels. Maximum levels of cytokine induction were measured within 0.5 to 1 
hour post infection, strongly implicating virus binding and/or entry as the initial triggers 
of altered cytokine gene expression.    
 
Use of a mouse diarrhea model demonstrated an additional biologic activity of the 
EIAV17 SU protein (and its V6 peptide) {Ball et al., 2005}. SU17 and SU19 proteins were 
given to mouse pups and the pups scored for diarrhea over a period of 12 hours. SU17 
induced significant dose dependent diarrhea in the model while SU19 did not {Ball et al., 
2005}.  Use of synthetic peptides in the mouse diarrhea model revealed that the V6 
region of SU17, but not SU19 was induced a dose dependent diarrhea.  Thus SU17 and 
SU19, and their V6 peptides have distinct biological activities in a mouse diarrhea model 
for viral enterotoxins {Ball et al., 2005}.   
  
1.5 SU Variable Region 6 (V6)  
The studies described above lead Payne and Fuller to further investigate the contribution 
of the V6 region of EIAV SU to altered disease expression (virulence phenotype). Thus 
they generated viruses with chimeric SU proteins. The chimeric SU proteins targeted V6 
from EIAV17SU and EIAV19SU. The SU proteins differ at 8 of 13 amino acids in the V6 
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region, with other amino acid differences scattered throughout SU.  The amino acid 
changes are non-conservative and V6 is the most divergent region between the two SU 
proteins. By creating chimeric clones that specifically target the V6 region from virulent 
and avirulent viruses, the hypothesis that V6 plays a role in virulence was tested. The V6 
chimeric viruses were constructed to replace the 19V6 sequence with the V6 from 
EIAV17 (Appendix I, Figure 2). This virus is referred to as EIAV17V6/19SU. The V6 region 
of EIAV19 was likewise placed into the background of the EIAV17 env gene.  This 
construct is called EIAV19V6/17. These two viruses share identical LTRs, gag, pol, S2 and 
TM. EIAV17 differs from EIAV19V6/17 by ~13 amino acids.  EIAV19SU differs from 
EIAV17V6/19SU by ~ 13 amino acids.  
 
The results of the V6 swaps were subtle, but show the sequence of the V6 region does 
impact virulence phenotype (Appendix I, Figure 2). Four out of four EIAV17 infected 
ponies experienced febrile episodes that began on, or before, day 11 post-infection. .  
The maximum recorded temperatures were 102°F to 106°F for EIAV17 infected ponies 
and febrile episodes were accompanied by thrombocytopenia {Fuller, unpublished}. 
Placing the V6 sequence from EIAV 19SU in the context of EIAV17 resulted in febrile 
episodes at 11 and 12 dpi in two ponies, a febrile episode at 35 dpi in an third animal and 
no febrile episode prior to day 40 in the final pony. Among the 4 ponies infected with 
EIAV19V6/17, 2 had normal body temperatures through day 25 post-infection and 2 
animals reached 104°F to 105°F, all displayed mild thrombocytopenia. In contrast, 
neither of the 2 ponies infected with the EIAV17V6/19SU viral construct experienced a 
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febrile episode through 40 days post infection and both maintained a normal platelet 
counts {Fuller, unpublished}. The clinical course of these two animals was 
indistinguishable from EIAV19SU/17TM infected Shetland ponies {Payne et al., 2004}. 
 
Peripheral blood mononuclear cells were collected from Shetland ponies infected with 
EIAV17, EIAV17V6/19SU and EIAV19V6/17SU. PBMC were collected at 12, 14, 15 and 17 
days post-infection and gene expression levels of IL-8, IL-1α, IL-1β, and TNF-α were 
measured by quantitative PCR. Figure 1.4 shows a summary of this data {Covaleda, 
unpublished}.  A review of the gene expression patterns shows that of the three infecting 
virus stocks, EIAV17 has a unique profile.  Most notably, IL-1α IL-1β and IL-8 gene 
expression levels are decreased in the EIAV17 infected ponies. This is reflected in the 
overall averages, and was also consistent for individual ponies.  While the absolute 
decreases are modest (a maximum of 2-fold) the overall trend is in sharp contrast to the 
trend of increased levels of IL-1α and IL-1β gene expression levels in ponies infected 
with either EIAV 19V6/17 (moderately virulent) or EIAV 17V6/19SU (avirulent). Thus the 
EIAV17 SU sequence is unique and V6 sequences contribute to the virulence phenotype. 
However, V6 alone is not sufficient to change the avirulent EIAV 19SU/17TM to the high 
virulence phenotype of EIAV17 and is not the only contributor to cytokine gene 
expression levels.  
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Figure 1.4- Average changes in gene expression during EIAV infection.  The data for EIAV17 and  
EIAV19V6/17 represents averages of 4 animals.  EIAV17V6/19SU data are average values from 2 
ponies.  All qPCR assays were done in triplicate.  Statistical significance was not determined due 
to the low number of animals used.   
 
 
 
The largest increases in TNF α, IL-8, and IL1β were in the 2 ponies infected with EIAV 
17V6/19SU, neither of which experienced a febrile episode. It appears that avirulent EIAV 
17V6/19SU may be associated with higher expression levels of proinflammatory cytokine 
genes than moderately virulent EIAV 19V6/17; however it is not possible to determine 
statistical significance of this observation, given the low numbers.  
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1.6 Hypothesis and Objectives 
The goal of my research project was to examine the viruses described above for their 
role in increased cytokine/chemokine gene expression in cultured macrophages. It was 
hypothesized that V6 plays a major role in virulence by inducing cytokine induction 
upon binding of macrophages.  Thus, there would be a positive correlation between the 
presence of V6 from a virulent strain and cytokine production.  It was also hypothesized 
that cultured macrophages could be used as a surrogate for animal studies.  If so, the 
results obtained from in vitro studies would be repeatable in an in vivo model.   
 
The specific objective of this study was to: 
1. Determine the role of the V6 region on cytokine expression in cultured eMDM  
a. Construct 2 chimeric viruses specifically isolating the V6 region using 
site-directed mutagenesis and PCR; 
b. Measure cytokine cDNA levels of IL-8, IL-1α, IL-1β, and TNF-α in 
eMDM infected with either virulent EIAV17 or avirulent EIAV19 using 
QPCR; 
c. Measure cytokine cDNA levels of IL-8, IL-1α, IL-1β, and TNF-α in 
eMDM infected with EIAV17V6/19SU or EIAV19V6/17SU using QPCR. 
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Animals 
Six outbred horses (#2000, #2230, #91, #2153, #2165, and Eli) owned by Texas A&M 
University were used in this study.  Horses were housed on a pasture at Veterinary 
Medical Park which is an AAALAC-accredited facility on the campus of Texas A&M 
University.  Horses were cared for according the Guide for the Care and Use of 
Laboratory Animals.  All horses had an annual Coggins test to ensure EIA negative 
status, were current on all required vaccinations and were in good health at the time of 
the blood collection.   All procedures were approved by the Institutional Animal Care 
and Use Committee. 
 
2.2 Virus Production and Purification 
Molecular clones for EIAV17 and EIAV19WyoLTR were constructed by the Payne 
laboratory as previously described {Payne et al., 1998; Payne et al., 2004}.  The Payne 
laboratory used those molecular clones to construct 2 chimeric viruses specifically 
isolating the V6 region (Figure A1) using PCR.    The constructs consisted of swaps of a 
28 amino acid region encompassing V6.  To create a chimeric virus with the V6 region 
of EIAV17 onto EIAV19 WyoLTR  (EIAV17V6/19SU), PCR was used to generate 3 products: 
EIAV 19SU 5’ (424bp), EIAV 19SU 3’ (993bp) and 17V6 (229 bp).  The three products 
were joined via overlap extension PCR to generate a chimeric 1.5 kb SU fragment 
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containing unique Sph1 and BstEII sites at its 5’ and 3’ ends respectively.  This 1.5 kb 
fragment was cloned into pDONR201 and following sequencing confirmation the 
fragment was excised by restriction digestion with SphI/BstEII and moved into 
Sph1/BstEII digested EIAV19/WyoLTR to generate the final infectious provirus, 
EIAV17V6/19SU. The final clone was again verified by the SU region sequencing. 
The chimeric EIAV19V6/17SU virus was also constructed by generating a chimeric env 
fragment by overlap extension PCR.  In this instance the V6 region was derived from 
EIAV19 and the 5’ and 3’ flanking fragments derived from EIAV17.  The resulting 1.5 kb 
fragment was cloned into pDONR201 and sequence verified.  A 720 bp HindIII 
fragment containing the V6 swap was then purified and ligated into a HindIII digested 
and gel purified EIAV17∆BamHI  (EIAV17 lacking a 2.6 kb BamHI fragment from the gag-
pol region) provirus.  PCR screening was used to identify recombinant clones and 
sequencing was performed to identity a construct with the HindIII fragment in the 
desired direction.  EIAV19V6/17∆BamHI was then digested with BamHI and ligated to a gel 
purified BamHI fragment from EIAV17 to regenerate a complete infectious provirus 
containing the V6 swap.  Colonies with the correct orientation of the BamHI fragment 
were identified and verified by sequencing.  This two-step cloning procedure was used 
simply to facilitate gel purification and recovery of the desired fragments.   
Plasmid constructs of complete EIAV proviruses and chimeras were transfected into 
D17 (canine) cells with a calcium phosphate transfection kit (Invitrogen).  Culture 
supernatants were collected at 48, 72, and 96 hours post-transfection.  Culture 
supernatants were tested for the presence of reverse transcriptase (RT) using [3H]TTP 
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{Payne et al., 2004}.  RT values greater than 3 times the values of the uninfected 
controls were considered positive for viral growth.  One-milliliter aliquots of positive 
D17 cell supernatants were then passed onto eMDM to generate virus stocks.  eMDM 
culture supernatants were collected 3, 7, and 13 days post infection and tested for the 
presence of RT.  Virus stocks were concentrated and cell-secreted molecules removed 
from clarified culture supernatants by ultrafiltration against at least 10 volumes of  fresh 
complete MEMα using a Vivaflow 200 tangential-flow ultrafiltration unit (Sartorius 
corp. Edgewood, NY) with a MWCO of 100kDa {Lim et al., 2005}.  Lim et al. have 
reported that ninety-six percent of non-viral proteins and cytokines with molecular 
weights between 7 to 75 kDa are removed under these conditions {Lim et al., 2005}.  
RT activity of the concentrated viral stocks was measured post-filtration and the cpm/ml 
was calculated.  Culture supernatant of mock-infected eMDM was collected and filtered 
under identical conditions and used as a control medium (CM) for the experimental 
infections.  Virus stocks were normalized based RT activity and the amount of SU 
protein determined via Western blot.  
 
2.3 eMDM Culture 
Whole blood was collected from EIA-negative horses into an anticoagulant citrate 
dextrose (ACD) solution blood collection bottle (The Metrix Company, Dubuque, Iowa).  
As described by Lim, blood was centrifuged at 1900 x g for 30 minutes to separate the 
buffy coat layer which was then centrifuged through a HybriMax histopaque cushion (d= 
1.077 g/cm3; Sigma, St. Louis, MO) to separate peripheral blood mononuclear cells 
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(PBMC’s) {Lim et al., 2003} .  PBMC’s were washed four times with Dulbecco’s Ca2+ 
and Mg2+ - free phosphate buffered saline (PBS) (Sigma, St. Louis, MO), 5% adult 
horse serum (endotoxin and EIA tested, Invitrogen/Gibco, Carlsbad, CA) and 1% 
penicillin-streptomycin solution (Sigma, St. Louis, MO).  PBMC’s were resuspended in 
Modified Eagles Medium alpha (MEMα) with 10% horse serum, 15 mM HEPES, 2 mM 
L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin to a concentration of 12 X 
106 cells/ml.  One-ml aliquots of the cell suspension were added to each of the 12-wells 
of a Poly-D-Lysine plate (Becton Dickinson Labware) and incubated at 37 °C in 5% 
CO2.  Non adherent cells and blood products were removed 24 hours after plating by 
washing with warmed (35o C) 1X PBS.  The plates were returned to the incubator for 72 
hours to allow for monocyte maturation into macrophages.  Maturation was determined 
by daily visual inspection of the cells in each plate.  
 
2.4 Immunoblotting 
To determine the amounts of SU protein relative to RT activity for the four virus stocks, 
60,000 cpm of RT activity were pelleted by centrifugation at 13000 x g for 2 h at 4 ºC. 
Viral pellets were resuspended in RIPA buffer, separated by 10% SDS-PAGE, 
transferred to nitrocellulose and analyzed by Western blotting. Primary antibody to 
EIAV SU was a mouse monoclonal antibody specific to EIAV SU (gp90(A)-86) 
obtained from NIH AIDS Research and Reference Reagent Program {Hussain et al., 
1987} and used at a dilution of 1/200 in Tris-buffered saline and 0.05% Tween 20 (TBS-
T) plus 5% non-fat dry milk. After overnight incubation at 4 ºC, membranes were rinsed 
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three times for five minutes in TBS-T and then incubated for 1 h at room temperature 
with goat anti-mouse HRP at a dilution 1:3000 (Pierce). The membrane was rinsed again 
and incubated with SuperSignal West Femto maximum sensitivity substrate (Pierce) for 
4 minutes and imaged using x-ray film. 
 
2.5 Infection of eMDM 
Five treatment groups were used:  EIAV17, EIAV19, EIAV17V6/19SU, EIAV19V6/17SU, and 
media/uninfected control.  Cells collected at four time points were tested for each 
treatment group: 30 minutes post infection (mpi), 1 hour post infection (hpi), 2 hpi, and 
4 hpi.  Previous studies by Lim and colleagues showed cytokine induction within 30 mpi 
with minimal differences past the 4hpi time point {Lim et al., 2005}.  Cultured eMDM 
were treated with equal amounts of virus and incubated in a 37°C incubator with 5% 
CO2.  At each time point, media was removed and the cells were lysed with RLT buffer 
from the Qiagen RNeasy Kit (QIAGEN, Valencia, CA.).  Lysates were collected after 
the addition of the buffer and stored at -80o C until ready for RNA isolation. 
 
2.6 RNA Isolation and cDNA Synthesis 
RNA was isolated from lysates using the Qiagen RNeasy Mini Kit (QIAGEN, Valencia, 
CA.)  according to the manufacturer’s instructions for total isolation of RNA from 
animal cells.  In order to eliminate DNA contamination, the extracted RNA was treated 
with 1µl of DNase 1 (Invitrogen, Carlsbad, CA).  RNA was quantified using a Nanodrop 
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Spectrophotometer ND1000 (Thermo Scientific, Wilmington, DE).  RNA was stored at -
80° C until used for cDNA synthesis. 
 
cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Carlsbad, CA).  Briefly, 2 µl of 10X RT Buffer, 1 µl of 100mM 
dNTP mix, 2 µl Random Primers, 1 µl Reverse Transcriptase, and nuclease-free H2O 
was added to 1µg of RNA for a total volume of 20 µl.  The reaction conditions used 
were as follows: 25°C for 10 minutes, 37°C for 120 minutes, and 85°C for 5 minutes.  
cDNA was stored at -20° C. 
 
2.7 qPCR 
Taqman primer and probe sets, obtained from Applied Biosystems, were designed for 
each cytokine (See Table 2.1) and extensively validated {Allen et al., 2007; Payne and 
Covaleda unpublished}. qPCR reactions contained Custom Taqman Gene Expressions 
Assay Mix containing primers and probes (Applied Biosystems, Carlsbad, CA), Taqman 
Universal PCR Master Mix containing Taq, dNTPs, and buffer (Applied Biosystems, 
Carlsbad, CA), 1.2 µl of cDNA and nuclease-free water for a total volume of 10 µl per 
reaction.  All qPCR measurements were run on ABI 7900HT real time PCR system 
using 384 well plates.  Each reaction was run in triplicate.  Amplification was carried out 
using the following parameters: 1 cycle at 50o C for 2 minutes, 1 cycle at 95o C for 10 
minutes, followed by 40 cycles of 95o C for 15seconds and 55oC for 20 seconds.  
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Changes in the gene expression level of 4 cytokines/chemokines: IL-8, IL-1α, IL-1β, and 
TNF-α were determined.   
 
 
Table 2.1. Primer and probe sequences used for Taqman PCR 
Primer Name Primer Sequence  
Equine IL-8 forward 5’-GCCACACTGCGAAAACTCA-3’ 
Equine IL-8 reverse 5’-GCACAATAATCTGCACCCACTTTG-3’ 
Equine IL-8 probe 5’-ACGAGCTTTACAATGATTTC-3’ (FAM6) 
Equine IL1-α forward 5’-CAATATCTTGCGACTGCTGCATTAA-3’ 
Equine IL1-α reverse 5’-CTCTTCTGATGTATAAGCACCCATGT-3’ 
Equine IL1-α probe 5’-ACGCAGTGAAATTT-3’  (FAM6) 
Equine IL1-β forward 5’-TGTACCTGTCTTGTGGGATGAAAG-3’ 
Equine IL1-β reverse 5’-GCTTTTCCATTTTCCTCTTTGGGTAA-3’ 
Equine IL1-β probe 5’-CCTACAGCTGGAGACAGT-3’ (FAM6) 
Equine TNF-α forward 5’-TTCTCGAACCCCAAGTGACG-3’ 
Equine TNF-α reverse 5’-GCTGCCCCTCGGCTT-3’ 
Equine TNF-α probe 5’-ATGTTGTAGCAAACCC-3’ (FAM6) 
18s forward 5’-AAACGGCTACCACATCCAA-3’ 
18s reverse 5’-TCGGGAGTGGGTAATTTGC-3’ 
18s probe 5’-AAGGCAGCAGGCGC-3’ (FAM6) 
 
 
2.8 Data Analysis 
qPCR data was collected and analyzed with the SDS 2.3 software which is designed for 
the ABI 7900HT real time PCR system.  The software detects and determines the 
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threshold cycle (Ct), the level at which the fluorescence gives a signal over the 
background, and displays it as the linear portion of the amplified curve.  The Ct value 
was used to quantify gene expression using the 2-ΔΔCt method, also known as the 
comparative threshold cycle (Ct) or ΔΔ Ct method (Livak and Schmittgen, 2001).  The 
value for each sample was normalized relative to the expression of the 18S rRNA gene 
as described in Applied Biosystems User Bulletin No. 2 (P/N 4303859). Changes in gene 
expression mediated by each virus (treatment) were compared to the media control 
(untreated). Fold changes in gene expression were also compared between treatments. A 
twofold change from baseline was considered to be significant.  Statistical analysis was 
completed with the assistance of the Texas A&M Department of Statistics.   Data was 
analyzed first with the Shapiro-Wilk test to ensure normal distribution and then with the 
Levine test to ensure equal variances.  A linear mixed model to determine the statistical 
significance of the cytokine/chemokine gene expression in respect to each virus and time 
point (Appendix II).     
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CHAPTER III 
RESULTS 
 
3.1 Analysis of Viral Stocks 
Stocks for each of the viruses under study were generated by primary transfection into 
D17 cells following by a single passage onto eMDM.  The development of cytopathic 
effects (data not shown) and RT assays of culture supernatants (Table 3.1) showed that 
the newly constructed V6 chimeric viruses were replication competent.  
 
Table 3.1.  Reverse transcriptase titers: Virus stocks 
Virus Sample CPM/ML  
EIAV17 1.3 x 106 
EIAV19 5.8 x 105 
EIAV17V6/19SU 6.9 x 105 
EIAV19V6/17 2.8 x 105 
 
 
Equal amounts of each virus stock (based of cpm/ml) were concentrated by 
centrifugation and analyzed by Western blot using a monoclonal antibody to a conserved 
SU epitope (Figure 3.1).  A visual examination of the blot showed that each stock 
contained approximately the same amount of SU per cpm. Thus eMDM were infected 
with equivalent cmp of each virus stock. 
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3.2 qPCR Results 
The expression of IL1-α, IL1b, IL8, TNF-α and 18S rRNA (housekeeping gene) were 
measured for each sample. All qPCR assays were run in triplicate for a total of 1800 
reactions.  Each 384-well plate contained all the genes and time points for one horse and 
each plate was run one time. The 18S ribosomal RNA was the baseline to which all other 
genes were compared.  The raw data are provided in Appendix II. Gene expression for 
TNF-α was not determined in four of the six horses so no results for TNF-α were 
included in the data sets or in the statistical analysis. 
 
3.3 Statistical Analysis 
Statistical analyses was performed to more rigorously examine the data. The model 
chosen for analysis was a linear mixed model.  This model was chosen because it takes 
into account random effects as well as fixed effects.  For this model, the fixed and 
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random effects are assumed to have a normal distribution.  In our model, the horse was 
the random effect and the virus and time points were the fixed effects.    
 Yijk= µ + horsei + virusj + timek  
A Shapiro-Wilk test was used in order to determine if the residuals were normally 
distributed (as required by the linear mixed model). The analysis indicated that the data 
from 5 of the 6 horses had normally distributed residuals and we could proceed with the 
data analysis using the linear mixed model.  These data are shown in Appendix II. 
 
3.4 Data Analysis 
Figures 3.2-3.4 show the change in gene expression for each treatment for each horse 
through the time course of the experiment. For each horse, the control media responses 
were set to 1 (baseline).  When graphed in this manner it is evident that there were 
considerable differences in responses among horses, as expected for outbred animals.  
For example, expression of IL8, as a result of EIAV17 treatment was increased by 3.5 
fold at 0.5 h for horse #2153 while remaining at baseline for horse #2000.  IL1-a 
expression was even more variable between individual horses. With EIAV17 treatment 
the expression of IL-1a was increased by 14-fold (at 0.5 h) for horse Eli but again 
remained at baseline levels for horse #2000.  The data for expression of IL-1b reveals 
similar differences between horses, with EIAV17 treatment inducing a 10-fold increase in 
gene expression for horse Eli at the 1 h timepoint while #2000 shows no change above 
baseline. Though responses for each horse are variable, it does appear that treatment 
with EIAV17 caused the greatest fold-changes in expression for each of the three genes 
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assayed, in accordance to data previously reported by Lim {Lim et al., 2005}.  
Examining individual horse responses for the other three treatments did not reveal any 
obvious pattern.  
 
While there was significant variation between horses, making individual comparison 
difficult, a sufficient number of horses were used to allow for a comparison of the mean 
fold change at each time point, as shown in Figure 3.5.  
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Figure 3.2- Change in IL-8 gene expression.  Change in gene expression for each virus treatment 
for each horse through the time course of the experiment. The control media responses were set to 
1 (baseline) for each horse.   
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Figure 3.3- Change in IL-1α gene expression.  Change in gene expression for each virus 
treatment for each horse through the time course of the experiment. The control media responses 
were set to 1 (baseline) for each horse.   
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Figure 3.4- Change in IL-1β gene expression.  Change in gene expression for each virus 
treatment for each horse through the time course of the experiment. The control media responses 
were set to 1 (baseline) for each horse.   
 
 
 
Examination of Figure 3.5 shows the average changes in genes expression level (versus 
control media) for each virus.  For the three genes measured, the fold-increases in 
expression were the most dramatic when cells were treated with EIAV17. Expression of 
IL-1a increased 3 fold at 0.5 h, rose to 6 fold by 1 h and dropped back to 3 fold by 4 
hours. A similar pattern was seen for IL-1b gene expression. Gene expression of IL-8 
gene was 2-fold at 0.5 h with the maximum fold-increase (2.5 fold) at 1 hpi. Treatment 
of eMDM with the EIAV19 virus stock resulted in much more modest changes in gene 
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expression. The expression of IL-1a was the most effected by EIAV19 treatment; IL-1a 
mRNA levels were 2-fold above the control at 0.5 hpi and transiently rose to 5-fold at 1 
hpi before falling to background levels by 4 hpi. IL-1b expression rose only marginally, 
to 2-fold over background levels at 1 hpi but then dropped by 2 hpi. The IL-8 data 
suggests some slight level of increase with EIAV19 treatment, but never reaches 2-fold.  
Somewhat unexpectedly, the two chimeric viruses showed similar effects on cytokine 
gene expression, and appeared to be no different than the EIAV19 virus. Expression of 
IL-1α was increased for all four virus infections compared to control media at 0.5 hpi 
indicating that cytokines are induced early, and that changes in gene expression are may 
result from virus or entry. Gene expression levels then dropped over the course of the 
experiment, returning to background levels for EIAV19 and the two chimeric viruses.  
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Figure 3.5- Average changes in gene expression levels.  Mean fold changes in gene 
expression (relative to mock infected control). Values are averages for all donor horses.  
eMDM infected with 17b (■), 19 (▲), 17V6 (><), 19V6 (>●<).  
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CHAPTER IV 
SUMMARY 
 
EIAV is a lentivirus in the family Retroviridae that infects equids including horses, 
donkeys, and mules.  EIAV infection is rarely fatal but results in a persistent life-long 
infection for which there is no treatment or cure.  Because there is no vaccine or 
preventative therapy, horses that test positive for EIAV must be quarantined for life, 
cannot travel, and are often euthanized to limit the spread of the virus.  The virus was 
discovered in 1904 but was not actively controlled until 1975 when a diagnostic test, 
Coggin’s test, was available and testing became widely accepted.  Today, EIAV is most 
frequently diagnosed in apparently healthy equids because of required surveillance 
testing when animals are moving interstate, going to congregation points, and at transfer 
of ownership.  {Issel, 2010} 
 
The outcome of an infection with EIAV is determined by a number of factors including 
the host immune system, the virus, and environmental factors.  Some viral strains will 
greatly impact one species but have no effect in another.  Infected animals may shed 
high levels of virus that is transmitted quickly to surrounding susceptible animals 
particularly if the infected animal is stressed or immunosuppressed.  The most common 
route of transmission is via mechanical transfer from one equid to another.  The major 
determinants of viral transfer are the level of virus in the blood and the amount 
transferred.  The vector with the highest potential of transmission is man because large 
 40 
 
amounts are transferred via blood transfusion and biological agents.  Insect vectors, 
including horse flies, dear flies, and stable flies, are frequently blamed as a common 
source of transmission.  The actual risk of transmission is extremely low even from 
horse with a high viremia because of the small amount of blood that is transferred from 
each insect.  {Issel, 2010} 
 
Once a horse is infected, it will develop a persistent, recrudescing viremia with variable 
clinical signs.  A typical pattern is that an animal that is initially infected will develop a 
high fever with concurrent anemia, thrombocytopenia, and weight loss.  Clinical signs 
are mediated by pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-8, and TNFα) when 
tissue associated viral burdens reach threshold levels. The acute disease usually resolves 
within a few weeks and the animal enters the chronic phase of the disease with 
reoccurrence of clinical signs over the course of a year with increased periods of latency 
between clinical signs.  Initial control of EIAV infections is mediated via cell mediated 
immunity with the humoral immune response requiring six to eight months to mature.  
Immune control is established only after the immune system has co-evolved with the 
virus to a fully mature state {Craigo et al., 2010}.  Once the viral replication has been 
controlled, the animal will remain free of clinical disease until a variant virus emerges 
that can evade immunological surveillance {Mealey et al., 2004}.  The viral replication 
does not stop as evidenced by the production of disease when blood is transmitted from 
an inapparent carrier to a naïve host. {Tornquist et al., 1997} 
 
 41 
 
EIAV has the ability to create quasispecies which produce escape mutants with the 
ability to evade the host immune system and induce additional clinical disease.  
Serologic and genetic characterizations of the evolution of EIAV quasispecies during 
chronic disease have demonstrated a close correlation between changes in viral 
neutralization specificity and variations in the sequence of the viral env glycoproteins, 
specifically in the gp90 region {Craigo et al., 2010}.  The evolution of the viral 
quasispecies is continuous and the natural variation observed in the quasispecies is a 
major challenge to vaccine development {Craigo et al., 2010}.  Ultimately, the capacity 
for the EIAV envelope to evolve and evade immune surveillance profoundly effects the 
ability of the animal to control the virus and impacts our ability to develop effective 
vaccines and therapeutics. {Craigo et al., 2013}  
 
The goal of the current study was to understand the role of one specific variable region 
in the complex SU protein and its impact on virulence.  By looking at cytokine induction 
in cells infected with variant viruses, we can determine if a specific region may have role 
in the overall virulence of the virus.  Then comparing data obtained in vitro with the in 
vivo pony data, we can clearly elucidate that the results may not be fully extrapolated 
into an in vivo model.  The current study using, QPCR as a method of detection, expands 
on current studies by Covaleda and the Payne lab {Covaleda et al., 2010}.  The study 
uses QPCR techniques that were validated by Allen and demonstrated by Covaleda 
{Allen et al., 2007; Covaleda et al., 2010}.   
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Cytokines are small proteins that act as signaling molecules to regulate inflammation 
and control cellular functions.  Cytokines are a diverse group of pro- or anti-
inflammatory factors that are grouped into families based on their structural homology 
or the structure of their receptors.  Chemokines are a subset of cytokines that induce cell 
migration.  Chemokines belong to two catagories based on their biological activities: 
maintenance of homeostasis through immune surveillance or induction of inflammation.  
The binding of a cytokine or chemokine to a cell sets off a cascade of events that 
regulate cell function such as cell adhesion, phagocytosis, cytokine secretion, cell 
activation, cell proliferation, apoptosis, angiogenesis, and proliferation.  All the 
cytokines included in this study are inflammatory mediators which would be activated 
during a viral infection.  {Ramesh et al., 2013; Tornquist et al., 1997} 
  
Interleukin- 1 (IL-1) consists of two molecules- IL-1 α and IL-1β.  IL-1 alpha and IL-1 
beta are cytokines that are primarily secreted by macrophages and have distinct roles in 
antibody production.  They have two main functions in that they assist leukocytes to 
migrate through vessel walls to the site of infection and acts on the thermoregulatory 
centers of the brain to raise the body temperature.   
 
IL- 8, also known as CXCL8, is secreted by macrophages, as well as other cells, upon 
phagocytosis of foreign material.  It has 2 primary functions: induce chemotaxis and 
induce phagocytosis.  It is also associated with inflammation and has been demonstrated 
to be overexpressed in chronic conditions such as cancer and hepatitis C virus infection.  
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The role of IL-8 in EIAV has yet to be determined but it may have opposing antiviral 
and proviral effects between acute and chronic disease states.  {Koo et al., 2006} 
  
TNF-alpha is an inflammatory cytokine that produces a myriad of responses in the body.  
Activation of TNF-α directly inhibits erythropoiesis and may be a primary contributor of 
the anemia associated with EIAV infection {Morceau et al., 2009}.  Our interest in this 
cytokine stems from its roll in chemotaxis and the induction of neutrophil proliferation 
as well as its role on fever induction.  Previous studies {Lim et al., 2005} demonstrated 
significant changes in the same cytokine/chemokines used for these experiments.  I used 
that data as a baseline to test my hypothesis that the V6 region of virulent EIAV17 is a 
key contributor to cytokine/chemokine stimulation post infection. 
 
Studies have clearly demonstrated that there is a significant increase in proinflammatory 
cytokines upon infection with virulent EIAV.  It is unclear why induction of TNF-α was 
so variable between the horses used in the in vitro studies.  Given that the animals are 
outbred and not genetically identical, some variation is expected.  However, given that 
TNF-α is strong contributor to the clinical signs expected with acute EIAV infection and 
a strong factor in the induction of anemia, it is surprising that there was not some 
consistency between the horses.   
 
My data revealed that the V6 chimeric viruses did not induce cytokine/chemokine 
expression levels above the avirulent EIAV19 virus.  The results showed that there is not 
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a strong correlation between the V6 region alone and cytokine induction, but did 
demonstrate that the V6 region is a component in the overall virulence of EIAV17.  
Additional studies involving the V6 region and other SU or TM regions will help 
understand the contribution of the variable regions to the induction of disease 
pathogenesis and clinical signs in horses.  The ultimate goal is to determine specific 
regions of the genome that can be targeted to create an effective vaccine against the virus 
that clearly distinguishable from natural infection.   
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APPENDIX I 
 
Figure A1- Top is a schematic of the 4 clones described in this proposal.  The black boxes 
represent sequences derived from the virulent Wyoming strain of EIAV.  The white boxes 
represent the nt sequences derived from avirulent culture adapted EIAV.  Bottom is a comparison 
of SU amino acids.  The EIAV 17 sequence is shown above; EIAV19 residues that differ are 
shown below.  The highlighted region represents the 28 amino acid region that is swapped in the 
chimeric viruses.  Figures obtained from Dr. Payne’s NIH grant.  
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Figure A2- EIAV proviral constructs with the V6 swap region (above).  In vivo temperature and 
platelet data (Fuller; 2011-2013).   
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APPENDIX II 
 
Statistical Analysis 
Data was analyzed using a linear mixed model.  This model was chosen for this data 
analysis because the model takes into account random effects as well as fixed effects.  
The fixed and random effects are assumed to have a normal distribution.  In our model, 
the horse was the random effect and the virus and time points as the fixed effects.    
 Yijk= µ + horsei + virusj + timek  
Before we could analyze the data sets with the model, we first performed a Shapiro-Wilk 
test in order to determine if the residuals were normally distributed.  If they were not, we 
would not be able to determine statistical significance of the results.  When we looked at 
the data from all six horses, we found that the residuals were not normally distributed 
(See Figure A3 and Figure A4).  This was attributed to outliers skewing the data. 
In order to obtain a data set that we could use to find statistical significance, we 
discarded the data from Horse 2230 and repeated the Shapiro-Wilk using the data from 
the remaining five horses.  This data set was determined to have normally distributed 
residuals (See Figure A5 and Figure A6) and we could proceed with the data analysis 
using the linear mixed model. 
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Figure A3- This plot shows that the residuals are not normally distributed; they should fall on a 
straight line.  This plot was created using data from all six horses. 
 
 
 
Figure A4- This plot shows how the residuals do not have constant variance because the 
scatterplot has a discernable trumpet pattern.   This plot is created using data from all six horses.  
This pattern is created by outliers specifically from data from Horse 2230. 
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Figure A5- There is no discernable pattern in the residuals, so you conclude that they have constant 
variance.  These plots were obtained using data from 5 horses and omitted the data from Horse 2230.
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Figure A6- The residuals fall along a straight line, so you conclude that they have a normal 
distribution.  These plots were obtained using data from 5 horses and omitted the data from Horse 
2230. 
 
 
 
 57 
 
qPCR Results: 
 
Once it was determined that the data was normally distributed and the residuals had a 
constant variance, thereby accepting the null hypothesis, the data was analyzed using the 
linear mixed model.  First the model determined the least squares means of each virus, 
which is the group means after having controlled for a covariate.  Then the model looks 
at the differences of least square means between each group.  There we look at the 
adjusted p-value to determine if the viruses are related or have a significant difference.  
A significant difference is determined by a p-value of < 0.05.  The least square means 
and differences of least square means were determined for each cytokine/chemokine 
gene expression.     
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Table A1- Least Means Squares to Determine Statistical Significance of 
Cytokine/Chemokine Gene Expresion: 
 
Data for IL-8: 
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